Paclitaxel and gemcitabine versus paclitaxel and vinorelbine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group (HeCOG)

1 Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type k-ras colorectal carcinoma Journal of Clinical Oncology, May 23, 2013

2 Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial The Lancet Oncology, June 11, 2013

3 Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States The American Journal of Gastroenterology, June 13, 2013

4 Asparagine synthetase is an independent predictor of surgical survival and a potential therapeutic target in hepatocellular carcinoma British Journal of Cancer, June 17, 2013

5 Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma Hepatology, May 23, 2013

6 Contribution of ADAMTS1 as a tumor suppressor gene in human breast carcinoma. Linking its tumor inhibitory properties to its proteolytic activity on Nidogen-1 and Nidogen-2 International Journal of Cancer, May 20, 2013

7 A phase II trial of neoadjuvant nab-paclitaxel, carboplatin, and gemcitabine (ACAG) in patients with locally advanced carcinoma of the bladder Urology, May 24, 2013

8 Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B Alimentary Pharmacology and Therapeutics, May 30, 2013    Evidence Based Medicine

9 Telomere length and risk of melanoma, squamous cell carcinoma, and basal cell carcinoma Cancer Epidemiology, June 17, 2013

10 Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of calgb 9343 Journal of Clinical Oncology, May 24, 2013